| 0.98 0.016 (1.66%) | 01-23 15:52 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.26 | 1-year : | 1.35 |
| Resists | First : | 1.07 | Second : | 1.15 |
| Pivot price | 1.02  |
|||
| Supports | First : | 0.94 | Second : | 0.79 |
| MAs | MA(5) : | 0.98 |
MA(20) : | 1.02 |
| MA(100) : | 1.03 |
MA(250) : | 1.23 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 9.6 |
D(3) : | 10.5 |
| RSI | RSI(14): 40.8 |
|||
| 52-week | High : | 4.17 | Low : | 0.76 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ADIL ] has closed above bottom band by 21.6%. Bollinger Bands are 9.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.02 - 1.03 | 1.03 - 1.03 |
| Low: | 0.94 - 0.94 | 0.94 - 0.95 |
| Close: | 0.95 - 0.96 | 0.96 - 0.97 |
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
Sat, 07 Dec 2024
Adial Pharmaceuticals revises CEO's compensation package - Investing.com
Tue, 03 Dec 2024
EXCLUSIVE: Adial Pharmaceuticals' Lead Drug Secures Key US Patent For Alcohol Dependence Based on Expanded Genotype Combinations - Benzinga
Tue, 03 Dec 2024
Adial Pharmaceuticals Secures Key Patent for Alcohol Use Disorder Treatment Technology - StockTitan
Mon, 25 Nov 2024
Adial Pharmaceuticals (ADIL) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Thu, 14 Nov 2024
Rodman & Renshaw sets stock target, buy rating on Adial Pharma, cites potential - Investing.com
Thu, 14 Nov 2024
Adial Pharmaceuticals completes key study for FDA meeting - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 6 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 3 (%) |
| Shares Short | 79 (K) |
| Shares Short P.Month | 78 (K) |
| EPS | -2.95 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.45 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -104.2 % |
| Return on Equity (ttm) | -321 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.34 |
| PEG Ratio | 0 |
| Price to Book value | 0.39 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|